Navigation Links
CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting
Date:5/21/2017

CNSDose is a genetically driven, clinically proven, decision support tool that helps avoid the lengthy trial and error process by finding the right antidepressant faster. CNSDose speeds recovery and reduces side effects for patients. It can also strengthen the doctor-patient relationship through a personalized approach to treatment.

A peer-reviewed and published, 12-week double-blind randomized controlled trial (RCT) that compared genetically guided and unguided antidepressant prescribing demonstrated positive results. The trial showed 72% of patients experienced full symptom recovery when using CNSDose compared to 28% of patients using trial and error. A recent review undertaken by the Department of Veterans Affairs Health Administration noted that, “CNSDose has the most favorable preliminary findings.” The CNSDose RCT was followed by another independent study, also peer-reviewed, that supported the RCT and showed > 85% accuracy, sensitivity, and specificity.

“We are thrilled to participate in the American Psychiatric Association Annual Meeting,” said Mark Heinemeyer, CEO of CNSDose. “This is where the leaders in psychiatry gather to learn and share new approaches – a perfect venue for us!”

Ajeet Singh MD PhD, Founder and Chief Science Officer of CNSDose, was recently published in The Journal of Precision Medicine in an editorial entitled Antidepressant Pharmacogenetics (Singh, Ajeet, & Bousman, Chad (2017). Antidepressant Pharmacogenetics. The Journal of Precision Medicine, 174:5, 417-418.). This editorial points to the impact that this type of testing can have, “…it is important for clinicians to keep abreast of this evolving area to best facilitate informed discussions with patients….genetically guided antidepressant prescribing may become part of routine clinical practice.”

Chief Medical Officer of CNSDose, Harris Eyre MD PhD, will be presenting at a symposium at the APA Annual Meeting. Representatives for CNSDose will be available at booth #2223. Advance meetings may be scheduled by calling 888.858.6285 x 2.

About CNSDose

CNSDose is a genetically driven, clinically proven, decision support tool that helps avoid the lengthy trial and error process by finding the right antidepressant faster. CNSDose speeds recovery and reduces side effects for patients. According to a review undertaken by the Department of Veterans Affairs on pharmacogenomics-guided antidepressant treatment, “CNSDose has the most favorable preliminary findings.” For more information, please visit: https://www.cnsdose.com/

Read the full story at http://www.prweb.com/releases/2017/05/prweb14353739.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Thermo Fisher Scientific Demonstrates Improved differentiation of Stem Cell-derived Neurons and Downstream Applications
2. PathSensors Demonstrates Breakthrough Mail Security Screening Solution at National Postal Forum 2017
3. BESI Full Scale Advanced Gasification Research Facility in University Park, Il Demonstrates Clean Waste Conversion for US Military
4. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
5. Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model
6. Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in pediatric patients
7. Clinical Utility of Biocepts Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium
8. ProMetics PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis ("IPF") Phase 2 Clinical Trial
9. New Clinical Study Demonstrates Feasibility of Performing Multiplex ANA Testing on Whole Blood via Finger-Stick in Physician Office Near-Patient Setting
10. Bird Rock Bios Gerilimzumab, an Anti-IL-6 Antibody, Demonstrates Potential for Affordable Global Access to a Novel Biologic to Treat Rheumatoid Arthritis
11. New Persephone Technology to Be Demonstrated at Genome Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2017)... ... September 14, 2017 , ... ... of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary materials that ... human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio will radically ...
(Date:9/14/2017)... , ... September 14, 2017 , ... One of the ... Saturday, Sept. 16. , For six hours that day, the GenCure Marrow Donor Program ... more than 30 H-E-B grocery stores in San Antonio. , The registration tables will ...
(Date:9/13/2017)... ... September 13, 2017 , ... AMRI, a global contract ... patient outcomes and quality of life for more than 25 years, today announced ... expert to the International Standards Organization/Technical Committee 194: Biological and Clinical Evaluation ...
(Date:9/12/2017)... ... September 12, 2017 , ... Avomeen.com, the analytical ... and development companies will be exhibiting at the 16th annual Contract Pharma Conference ... Pharma is an educational conference for pharma and bio-pharma professionals that has ...
Breaking Biology Technology:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):